Last reviewed · How we verify

NCT07316556: Vliwazell

Post-Marketing Surveillance of Vliwazell® Prowound Dressing

Recruiting now Last updated 5 January 2026
What this trial tests

trial in Acute and Chronic Wounds in 208 participants. Currently enrolling.

Timeline
11 March 2024
Primary endpoint
31 January 2027
31 January 2027

Quick facts

Lead sponsorLohmann & Rauscher
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment208
Start date11 March 2024
Primary completion31 January 2027
Estimated completion31 January 2027
Sites8 locations across Germany

Conditions studied

Sponsor

Lohmann & Rauscher

Who can join

18 and older, any sex, with Acute and Chronic Wounds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This PMCF study is conducted to confirm the effectiveness and safety of the wound dressing Vliwazell® Pro. The aim of the study is to validate the performance of Vliwazell® Pro within its intended purpose and certified indications during routine use, and to gather additional safety data. The study will examine how the use of the dressing affects the condition of the skin surrounding the wound, the wound status in terms of exudate, wound odor, and other parameters. Furthermore, the satisfaction of healthcare providers and patients with the application of the dressing will be assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Lohmann & Rauscher trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07316556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing